Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Lonigutamab by Acelyrin for Graves' Ophthalmopathy: Likelihood of Approval
Lonigutamab is under clinical development by Acelyrin and currently in Phase II for Graves' Ophthalmopathy. According to GlobalData, Phase II...